Shots:

• The P-III (ATTR-ACT) & LTE study evaluate Vyndaqel (20/80mg) vs PBO in patients with ATTR-CM. In the LTE study, patients were transitioned to the bioequivalent Vyndamax
• In an ATTR-ACT trial, Vyndaqel showed a 30% reduction in mortality @30mos. with a median follow up of ~5yrs., 41% reduction in risk of all-cause mortality in patients who received continuous treatment (median follow up 58.5mos.) compared to those who received PBO in ATTR-ACT (median follow up 57.1mos.), median survival (67mos. vs 35.8mis.), 5yrs. survival rate (53.2%)
• Additionally, 39% & 43% reduction in risk of all-cause mortality in patients with wild-type & hereditary ATTR-CM who received continuous treatment

Ref: Businesswire | Image: The Wall Street Journal